Submitted:
30 April 2024
Posted:
01 May 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Mitochondriopathies, Preferred Indications for Redox Regulation through Ozone
3. Evaluation and Discussion of the Relevant Data in Redox Regulation for Selected Mitochondriopathies
3.1. Reference Substances.
3.2. Toxicity of Ozone versus Therapeutical Efficacy
3.3. Evaluation of Mitochondrial Pathologies and the Regulatory Effect of Medical Ozone. Restoration of the Redox Balance
3.3.1. Osteoarthritis
3.3.2. Rheumatoid Arthritis.
3.3.3. Diabetes.
3.5.4. Oncology. Prevention from Side Effects of Chemotherapy.
3.5.5. Aging.
3.3.6. Prevention
4. Mechanism of Action
Conclusion and Future Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Löffler, Petridis. Biochemie und Pathobiochemie. [Biochemistry and Pathobiochemistry]. Springer publisher 2014. Berlin, Heidelberg.
- Sies, H. Oxidative Eustress: On Constant Alert for Redox Homeostasis. Redox Biol. 2021, 41, 101867. [Google Scholar] [CrossRef]
- Sies, H.; Jones, D.P. Reactive oxygen species (ROS) as pleiotropic physiological signaling agents. Nat. Rev. Mol. Cell. Biol. 2020. 21, 363–383. [CrossRef]
- Napolitano, G.; Fasciolo, G.; Venditti, P. Mitochondrial Management of Reactive Oxygen Species. Antioxidants 2021, 10, 1824. [Google Scholar] [CrossRef]
- Zhang, G.; Darshi, M.; Sharma, K. The Warburg Effect in Diabetic Kidney Disease. Manjula Seminars in Nephrology 2018, 38, 111–120. [Google Scholar] [CrossRef]
- Menendez, J.; Joven, J.; Cufi, S.; Corominas-Faja, B.; Oliveras-Ferraros, C.; Cuyàs, E.; Vazquez-Martin, A. The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle 2013. 12, 1166–1179. [CrossRef]
- Green,D. R.: Galluzzi,L.; Kroemer, G. Mitochondria and the Autophagy–Inflammation–Cell Death Axis in Organismal Aging. Science 2011, 333, 1109. [CrossRef]
- Bhatti, J. S.; Bhatti, G.K.; Reddy, P.H. Mitochondrial dysfunction and oxidative stress in metabolic disorders —A step towards mitochondria based therapeutic strategies. Biochimica et Biophysica Acta 2017, 1863, 1066–1077. [Google Scholar] [CrossRef] [PubMed]
- Thanan, R.; Oikawa, S.; Hiraku, Y.; Ohnishi, S., Ma; Pinlaor, S.; Yongvanit, P.; Kawanishi, S.; Murata, M. Oxidative Stress and its Significant Roles in Neurodegenerative Diseases and Cancer. Int. J. Mol. Sci. 2015, 16, 193–217. [Google Scholar] [CrossRef] [PubMed]
- Verschoor, M. L. ; Ungard,R. ; Harbottle, A.; Jakupciak, J. P.; Parr R. L.; Singh, G. Mitochondria and Cancer: past, present and future. BioMed Res Int. 2013, 2013, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Natarajan, V; Parinandi, N. (edts), Mitochondrial Function in Lung Healtr and Disease. Respiratory Medicine, Humana Press. 2014. ISBN 978-1-4939-0829-5 (eBook) Springer New York, Heidelberg, Dordrecht, London.
- Mawsouf, M.N.; El-Sawalhi, M.M.; Darwish, H.D.; Shaheen, A.A.; Martínez-Sánchez, G.; Re, L. Effect of ozone therapy on redox status in experimentally induced arthritis. Revista Española de Ozonoterapia 2011, 1, 32–43 https://wwwresearchgatenet/publication/277217462_Effect_of_ozone_therapy_on_redox_status_in_experimentally_induced_arthritis. [Google Scholar]
- Leon Fernandez, O.S.; Oru, G.T.; Vega, J.S.P.; Fernandez, E.G.; Viebahn-Hänsler, R.; Torres-Carballeira, R.; Cabreja, G. L.; Mendez, R.M. Ozone + Arthros¬copy: Improved Redox Status, Function and Surgical Outcome in Knee Osteoarthritis Patients. Int J Innov Surg. 2020, 3, 1011. https://mail.meddocsonline.org/international–journal. [Google Scholar]
- Fernández-Cuadros, M.E.; Pérez-Moro, O.S.; Albaladejo-Florín, M.J.; Tobar-Izquierdo, M.M.; Magaña-Sánchez, A.; Jiménez-Cuevas, P.; Rodríguez-de-Cía, J. Intra Articular Ozone Modulates Inflammation and has Anabolic Effect on Knee Osteoarthritis. IL-6 and IGF-1 as Pro-Inflammatory and Anabolic Biomarkers. Processes 2022, 10, 138. [Google Scholar] [CrossRef]
- León, F.O.S.; Viebahn-Haensler, R.; López, C.G.; Serrano, E.I.; Hernández, M.Y.; Delgado, R.L.; Tamargo, S.B.; Takon, O.G.; Polo, V.J.C. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Eur. J. Pharmacol. 2016, 789, 313–318. [Google Scholar] [CrossRef]
- Takon Oru, G.; Viebahn-Haensler, R.; García Fernández, E.; Alvarez Almiñaque, D.; Juan Polo Vega, C.; Tamargo Santos, B.; López Cabreja, G.; Serrano Espinosa, I.; Tabares Nápoles, N.; León Fernández, O.S. Medical Ozone Effects and Innate Immune Memory in Rheumatoid Arthritis Patients Treated with Methotrexate+Ozone After a Second Cycle of Ozone Exposure. Chronic Pain Manag. 2019, 2, 114. [Google Scholar] [CrossRef]
- León Fernández, O.S.; Oru, G.T.; Viebahn-Haensler, R.; López Cabreja, G.; Serrano Espinosa, I.; Corrales Vázquez, M.E. Medical Ozone: A Redox Regulator with Selectivity for Rheumatoid Arthritis Patients. Pharmaceuticals 2024, 17, 391. [Google Scholar] [CrossRef]
- Al-Dalain, S.M.; Martínez, G.; Candelario-Jalil, E.; Menendez, S.; Re, L. ; Giuliani, A,; León, O. S. Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacological Research 2001, 44, 391–396. [Google Scholar] [CrossRef] [PubMed]
- Martinez Sanchez, G,; Al-Dalain, S. M.; Menendez, S.; Re, L.; Giuliani, A.; Candelario-Jalil, E.; Alvarez, H., JI Fernandez-Montequin, J.L.; Leon, O.S. Therapeutic efficacy of ozone in patients with diabetic foot. Eur. J. Pharmacol. 2005, 523, 151–161. [CrossRef] [PubMed]
- Clavo, B.; Rodriguez-Esparragon, F.; Rodriguez-Abreu, D. ; Martinez-Sanchez,G. ; of Liontop, P.; Aguiar Bujanda, D.; Fernandez-Perez, L.; Santana-Rodriguez, N. Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. Antioxidants 2019, 8, 588. https://www.mdpi.com/2076–3921/8/12/588. [Google Scholar]
- Clavo, B.; Ruiz, A.; Lloret, M.; López, L.; Suárez, G.; Macías, D.; Rodríguez, V.; Hernández, M.; Martín-Oliva, R.; Quintero, S.; Cuyás, J. ; Francisco Robaina. Adjuvant Ozone therapy in Advanced Head and Neck Tumors: A Comparative Study. Evid Based Complemen Alternat Med. 2004, 1, 321–325. [Google Scholar] [CrossRef] [PubMed]
- Clavo, B.; Santana-Rodriguez, N.; Llontop, P.; Gutierrez, D.; Ceballos, D.; Mendez, C.; Rovira, G.; Suarez, G.; Rey-Baltar, D.; Garcia-Cabrera, L.; et al. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015, Article ID 480369. [CrossRef]
- Borrego, A.; Zamora, Z.B.; Gonzalez, R.; Romay, C.; Menendez, S.; Hernandez, F.; Montero, T.; Rojas, E. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats. Mediators Inflamm. 2004, 13, 13–19. [Google Scholar] [CrossRef] [PubMed]
- Safwat, M.H.; El Sawalhi, M.M.; Mawsouf, M.N.; Shaheen, A.A. ; Ozone ameliorates age related oxidative stress changes in rat liver and kidney: effects of pre- and post-aging administration. Biochemistry (Moscow) 2014, 79, 572–582. [Google Scholar] [CrossRef]
- León Fernández, O. S.; Takon Oru, G.; Viebahn-Hänsler, R.; López Cabreja, G.; Serrano Espinosa, I.; García Fernández, E. Medical ozone arrests oxidative damage progression and regulates vasoactive mediator levels in older patients (60-70 years) with oxidative etiology diseases. Front. Physiol. 2022, . https://www.frontiersin.org/articles/10.3389/fphys.2022. 03 November 1029. [Google Scholar]
- Léon, O.S.; Menendéz, S.; Merino, N.; Castillo, R.; Sam, S.; Pérez, L.; Cruz, E.; Bocci, V. Ozone oxidative preconditioning: A protection against cellular damage by free radicals. Mediat. Inflamm. 1998, 7, 289–294. [Google Scholar] [CrossRef] [PubMed]
- Viebahn-Haensler, R.; León Fernández, O.S.; Fahmy, Z. Ozone in medicine: The low-dose ozone concept. Guidelines and treatment strategies. Ozone Sci. Eng. 2012, 34, 408–424. [Google Scholar] [CrossRef]
- Fathi, A.M. Mawsouf, M. N.; Viebahn-Hänsler, R. Ozone Therapy in Diabetic Foot and Chronic, Nonhealing Wounds Ozone. Sci. Eng. 2012, 34, 438–450. [Google Scholar] [CrossRef]
- Torequl Islam, M.; Sarkar, C.; Hossain, R. , Bhuia, S. M.; Mardare, I.; Kulbayeva, M.; Ydyry, A.; Calina, D.; Habtemariam, S.; Kieliszek, M.; ShariL-Rad, J.; Cho, W.C. Therapeutic strategies for rheumatic diseases and disorders: targeting redox imbalance and oxidative stress Biomedicine & Pharmacotherapy 2023, 164, 114900. [Google Scholar] [CrossRef] [PubMed]
- Shehata, N.I.; Abd-Elgawad, H.M.; Mawsouf, M.N.; Shaheen, A.A. ; The potential role of ozone in ameliorating the age-related biochemical changes in male rat cerebral cortex. Biogerontology 2012, 13, 565–581. [Google Scholar] [CrossRef]
- Viebahn-Haensler, R.; León Fernández, O.S. Ozone as Redox Bioregulator in Preventive Medicine: The Molecular and Pharmacological Basis of the Low-Dose Ozone Concept—A Review. Int. J. Mol. Sci. 2023, 24, 15747. [Google Scholar] [CrossRef]
- Ajamieh, H.H.; Berlanga, J.; Merino, N.M.; Martinez Sanchez, G.; Carmona, A.M.; Menendez Cepero, S.; Giuliani, A. , Re, L. ; Leon, O.S. Role of protein synthesis in the protection conferred by ozone-oxidative-preconditioning in hepatic ischaemia/reperfusion. Transplant International 2005, 18, 604–612. [Google Scholar] [CrossRef]
- Viebahn-Haensler, R.; León Fernández, O. Ozone in Medicine. The Low-Dose Ozone Concept. The Redox-Bioregulatory Effect as Prominent Biochemical Mechanism and the Role of Glutathione. Ozone: Sci. Eng. 2023. [CrossRef]
- Togi, S.; Togi, M.; Nagashima, S.; Kitay, Y.; Muromoto, R.; Kashiwakura, J.; Miura, T.; Matsuda, T. Implication of NF-kB Activation on Ozone-Induced HO-1 Activation. BPB Reports 2021, 4, 59–63 doiorg/101248/bpbreports42_59. [Google Scholar] [CrossRef]
- Andreula, C.F.; Luigi Simonetti, L.; De Santis, F.; Agati, R.; Ricci, R.; Leonardi, M. Minimally Invasive Oxygen-Ozone Therapy for Lumbar Disk Herniation Am J Neuroradiol 2003, 24, 996–1000. PMC797 5773.
- Rashid, U.; Rauf, F. ; Hameedullah A,; et al. Ozonucleolysis in Cervical Radiculopathy. Neurol Res Surg. 2018, 1. [Google Scholar] [CrossRef]











| Mitochondrial pathologies | References |
|---|---|
| Aging, age-related diseases. Chronic inflammation | Douglas et al. 2011 [7] |
| Insuline resistance, diabetes 2, obesity, cardiovascular diseases, stroke | Bhatti et al. 2017 [8] |
| Neuro degenerative diseases, Cancer | Thanan et al. 2015, [9] Verschoor et al. 2013 [10] |
| Respiratory diseases | Natarajan et al. 2014 [11] |
| Pathology and type of study | Procedure | Oxidative stress/repair parameters here discussed | References |
| Chronic inflammatory processes | |||
| Knee osteoarthritis. | |||
| Preclinical trial in rats. Effect of intrarticular ozone application on redox status in experimentally induced arthritis. Preclinical trial | 6 groups, n=48. 5-6 mL rectal ozone application; 0.5-0.7-1.0 mg/kg rat (week 1 to 3), 15 applications in prevention, 10 in the therapeutic group | Ox stress: MDA Repair: GSH |
Mawsouf, N. et al. 2011 [12] |
| Ozone + Arthroscopy: Improved redox status, function and surgical outcome in knee osteoarthritis patients. Clinical trial | 40 patients. Group 1, n=20, surgical procedure by arthroscopy. Group 2, n=20, preventive ozone + arthroscopy. Rectal ozone insufflation. conc. 25-35 μg/mL, vol. 150-200 mL increasing in 4 weeks, 5x/week | Ox stress: MDA repair: GSH GGT Beginning after ozone and 30 days after ozone+arthroscopy, or arthroscopy alone |
León Fernández et al. 2020 [13] |
| Articular ozone modulates inflammation and has anabolic effect on knee osteoarthritis: IL-6 and IGF-1 as pro-inflammatory and anabolic biomarkers. Clinical trial | 51 patients (non diabetic, non-obese). 4 weeks, 1x/week, intraarticular 20 mL, conc. 20 μg/mL | Proinflammatory cytokine IL-6 | Fernández-Cuadros, et al. 2022 [14] |
| Rheumatoid arthritis | |||
| Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Clinical study |
60 patients, MTX group (n =30) basic therapy, MTX group with basic therapy (methotrexate + Ibuprofen + folic acid). Ozone group (n=30): treatment in the same way as the MTX group + ozone. Ozone treatment: 20 rectal insufflations 25–40 μg/mL, 150-200 mL during 4 weeks | Ox stress: MDA repair: GSH |
León et al. 2016 [15] |
| Medical ozone effects and innate immune memory in rheumatoid Arthritis patients treated with Methotrexate+ozone after a second cycle of ozone exposure. Clinical study | This study shows the same results as revealed by León et al. 2016, even better after a second cycle of ozone treatment due to the formation of memory cells during or after the first treatment cycle | Ox stress: MDA repair: GSH |
Takon-Oru et al. 2019 [16] |
| Medical Ozone: A Redox Regulator with Selectivity for Rheumatoid Arthritis Patients. Clinical study |
Although RA and osteoarthritis are of different origin both are compared concerning the impact of redox regulation through ozone as usual, see above | Ox stress: MDA repair: GSH |
León Fernández et al. 2024 [17] |
| Diabetes | |||
| Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model In rats. Preclinical study |
Preclinical trial with STZ (Streptozotocin) induced diabetes in in rats, n=50. As diabetes 2 is closely associated with oxidative stress, this animal model confirms the hypothesis that medical ozone is able to regulate and /or restore redox balance. Procedure: rectal insufflation with an ozone amount of 1.1 mg/kg rat, 10 treatments in 2 weeks | Ox stress: MDA repair: GSH |
Al Dalain et al. 2001 [18] |
| Therapeutic efficacy of ozone in patients with diabetic foot | Clinical study in diabetes patients with diabetic gangrene. Antibiotic group, n=49, received antibiotic infusions according to the specific germs. Ozone group, n=51, 20 rectal ozone insufflations, 5 per week 200 mL, conc. 50 μg/mL. Healing process improved, plasma glucose decreased. Oxidative stress decreased corresponding to an increase in SOD |
GSH, SOD as repair parameter. TH as oxidative stress parameter | Martínez-Sánchez et al. 2005 [19] |
| Cancer | |||
| Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: review and prospects | Improvement of clinical results. Further trials necessary | Review: no redox data available | Clavo et al. 2019 [20] |
| Cancer. complementary concept, head and neck tumors. | Comparative study. N=19. | Clinical data; no redox data availble. | Clavo et al. 2019 [21] |
| Radiation-induced rectal bleeding in prostate cancer | 12 patients successfully treated by rectal ozone insufflation | No redox data available. | Clavo et al. 2015 [22] |
| Protection by ozone preconditioning in cisplatin-induced nephrotoxicity in rats. Preclinical study |
Rectal insufflation, conc. 20+30 μg/mL, 15 applications over 3 weeks prior to cisplatin. 10 groups with 7 animals each, here cisplatin group as control and 2 ozone groups. | Ox stress: MDA repair: GSH |
Borrego et al. 2004 [23] |
| Aging | |||
| Ozone ameliorates age- related oxidative stress changes in rat liver and kidney: effects of pre- and post-aging administration. Animal trial | Ozone group: rectal ozone application regularly from month 4 through month 14 (3x per week, later 2x/week, ozone concentration: 20 mg/L, volume approx.. 5 mL corresponding to 0.6 mg/kg body weight) |
Ox stress: MDA repair: GSH |
Safwat et al. 2014 [24] |
| Medical ozone arrests oxidative damage progression and regulates vasoactive mediator levels in elderly patients (60–70years) with oxidative etiology diseases. Clinical study |
20 rectal ozone insufflations, 5 per week 200 mL, conc. 20 to 30 μg/mL. | Ox stress: MDA repair: GSH |
León Fernández et al. 2022 [25] |
| Oxidative stress markers | Protektive stress markers, antioxidants | Cytokines |
|---|---|---|
| TH ↓ total hydroperoxides |
Total SOD ↑ superoxide dismutase |
Interleukines IL-1, IL-6 ↓ TNF-α ↓ Tumor necrosis factor IFN-γ |
| MDA ↓ malondialdehyde |
GSH ↑↑ reduced glutathione |
|
| NO ↓ Nitrogen oxide |
γ-GT ↓ γ glutamyltransferase |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).